Organization | Krka

Krka Report issue

For profit Phase 4

Founded: Novo Mesto Slovenia (1954)

Status: No NME R&D (1954)

Organization Overview

First Clinical Trial

2018

NCT03738761

First Marketed Drug

2000

enalapril (vasotec)

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

KRKA | KRKA DD NOVO MESTO | KRKA TOVARNA ZDRAVIL

Active Ingredients

Marketed Drugs (2)

enalapril (vasotec) (2000)

lansoprazole (prevacid) (2013)

Drugs in Phase 4 Trials (5)

amlodipine (norvasc) (1 trial)

duloxetine (Cymbalta) (1 trial)

indapamide (lozol) (1 trial)

perindopril (aceon) (1 trial)

pregabalin (lyrica) (1 trial)

Drugs in Other Trials (6)

amoxicillin (1 trial)

bismuth (1 trial)

clarithromycin (biaxin) (1 trial)

esomeprazole (nexium) (1 trial)

levofloxacin (levaquin) (1 trial)

metronidazole (flagyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetic Neuropathies (Phase 4)

Hypertension (Phase 4)

Pain (Phase 4)

Peripheral Nervous System Diseases (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 11